Co-Authors
This is a "connection" page, showing publications co-authored by Philip Charles Hoffman and Theodore Karrison.
Connection Strength
0.155
-
Brief Report: Discordance Between Liquid and Tissue Biopsy-Based Next-Generation Sequencing in Lung Adenocarcinoma at Disease Progression. Clin Lung Cancer. 2023 05; 24(3):e117-e121.
Score: 0.055
-
A Phase 1 Trial of Concurrent or Sequential Ipilimumab, Nivolumab, and Stereotactic Body Radiotherapy in Patients With Stage IV NSCLC Study. J Thorac Oncol. 2022 01; 17(1):130-140.
Score: 0.050
-
Evaluation of a novel rash scale and a serum proteomic predictor in a randomized phase II trial of sequential or concurrent cetuximab and pemetrexed in previously treated non-small cell lung cancer. BMC Cancer. 2014 Jan 04; 14:5.
Score: 0.029
-
Refining epidermal growth factor receptor (EGFR) -inhibition-related rash (EIRR) phenotypes with a cetuximab (C) monotherapy stage of a phase II trial for non-small cell lung cancer (NSCLC). J Clin Oncol. 2008 May 20; 26(15_suppl):8089.
Score: 0.020